STERIS Raises FY27 EPS Outlook to $11.35-$11.55 on Tariff Refunds

STERIS plc reported fiscal 2027 second quarter revenue of $1.5886 billion, up 9% from $1.4603 billion a year earlier, with constant currency organic growth of 8.1%, the Dublin-based infection prevention and sterilization company announced on 4 November 2026. Diluted EPS rose to $2.19 from $1.94, and adjusted EPS climbed to $2.94 from $2.47. STERIS raised its full-year adjusted EPS outlook to $11.35-$11.55 from $11.10-$11.30, crediting solid underlying performance plus roughly $0.18 of benefit from tariff refunds received year-to-date.

Context — Why STERIS Raised Guidance Now

The revision lands two quarters into a fiscal year the company describes as shaping up to be another record. The prior outlook, issued before the tariff refunds were received, set adjusted EPS at $11.10-$11.30. The new range moves the floor up by $0.25 and the ceiling by $0.25, so the entire increase is not explained by the $0.18 refund benefit alone.

Management tied the raise to two things: stable underlying performance and cash recovered on tariffs previously paid under the International Emergency Economic Powers Act. That refund is a one-time cash item rather than an operating improvement, which matters for how investors read the quality of the beat.

Segment mix is the second driver. Life Sciences delivered what CEO Dan Carestio called "particularly strong performance," and the company raised that segment's full-year constant currency organic revenue growth outlook to 9-10% from 6-7%. Healthcare and Applied Sterilization Technologies guidance were left unchanged at 6-7% each.

The quarter also carried a $20 million pre-tax tariff refund benefit against $15 million of gross tariff costs, flat with the prior year. Net of that, the tariff line was a tailwind rather than the headwind it was a year ago.

Data — What the Q2 Numbers Show

Revenue of $1.5886 billion compared with $1.4603 billion in the second quarter of fiscal 2026, an 8.8% as-reported increase. Gross profit rose to $710.8 million from $645.9 million, with cost of revenues at $877.8 million versus $814.4 million.

Income from operations reached $294.3 million, up from $265.8 million. Net income attributable to shareholders was $213.7 million against $191.9 million. Adjusted net income was $286.8 million versus $244.5 million.

Metric	Q2 FY27	Q2 FY26	Change
Revenue	$1.5886bn	$1.4603bn	+8.8%
Diluted EPS	$2.19	$1.94	+12.9%
Adjusted EPS	$2.94	$2.47	+19.0%
Free cash flow (H1)	$492.5m	$527.7m	-6.7%

Segment revenue: Healthcare $1,122.4 million, up 8.6%; AST $295.6 million, up 5.0%; Life Sciences $170.6 million, up 17.7%. Life Sciences capital equipment revenue grew 53%.

Free cash flow for the first six months fell to $492.5 million from $527.7 million, which the company attributed to a significantly lower working capital contribution.

Analysis — What It Means for Medical Device Investors

Three second-order effects stand out. First, the tariff refund is non-recurring, so the $0.18 boost does not repeat in fiscal 2028 unless new refunds arrive. Investors modeling forward earnings should strip it out.

Second, the Life Sciences upgrade is the operationally meaningful signal. A 53% jump in capital equipment revenue in that segment suggests pharma and bioprocessing customers are spending again, a read-across for other capital equipment suppliers to life sciences end markets.

Third, cash conversion weakened. Operating cash flow fell to $656.1 million from $707.8 million, and the company spent $215.9 million repurchasing shares versus $111.1 million a year earlier. Buybacks absorbed cash that working capital had previously supplied.

The counter-argument: adjusted EPS excludes $65.0 million of acquired intangible amortization and $25.5 million of restructuring charges this quarter. On GAAP diluted EPS of $2.19, the growth rate is 12.9%, roughly half the adjusted figure.

Positioning-wise, the guidance raise and unchanged revenue outlook suggest management is defending the earnings line rather than the top line. Traders watching US equities will note the company did not raise consolidated revenue growth, which stays at 7-8% as reported.

Outlook — What to Watch Next

STERIS will host a conference call on 5 November 2026 at 9:00 am ET, with a replay available from noon ET the same day. That call is the first opportunity for analysts to press management on how much of the Life Sciences strength is durable versus order timing.

The company said it will provide revised fiscal 2027 guidance inclusive of the proposed Xodus Medical acquisition after closing. No closing date was disclosed, and no terms were given.

The restructuring plan approved during the quarter carries about $45 million in total charges, including $10 million cash and $35 million non-cash, with roughly $25 million booked in Q2. Expected annualized savings are about $9 million, with partial realization in fiscal 2028.

Watch the working capital line in the fiscal third quarter. If the H1 cash flow gap persists, the buyback pace and dividend growth become harder to sustain together.

Frequently Asked Questions

What does the STERIS guidance raise mean for retail investors?

The raise is mostly a tariff refund benefit plus better Life Sciences performance, not a broad demand upgrade. Consolidated revenue growth guidance was left unchanged at 7-8% as reported and 6-7% in constant currency organic terms. Retail investors should treat the $0.18 tariff contribution as non-recurring and focus on whether operating cash flow recovers in the second half.

Why did STERIS free cash flow fall despite higher net income?

Higher net income was more than offset by a significantly lower contribution from working capital in fiscal 2027 compared with fiscal 2026, the company said. Operating cash flow fell to $656.1 million from $707.8 million, and free cash flow dropped to $492.5 million from $527.7 million. Share repurchases also rose to $215.9 million from $111.1 million.

What is the Xodus Medical acquisition and when will it close?

STERIS referenced a proposed Xodus Medical acquisition and said it will provide revised fiscal 2027 outlook inclusive of the deal after closing. The company did not disclose the transaction terms, the purchase price, or an expected closing date in this release. Investors should expect updated guidance only once the acquisition completes.

Bottom Line

STERIS beat on adjusted EPS and raised guidance, but the increase leans on a one-time tariff refund and a single strong segment.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.